Does Rallies show Form 4 insider transactions for ADPT?

Yes. Rallies tracks ADPT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ADPT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ADPT. It does not provide personalized investment advice.

ADPT (Adaptive Biotechnologies Corporation Common Stock) Stock Analysis - Insider Trades

Adaptive Biotechnologies Corporation Common Stock (ADPT) is a publicly traded Healthcare sector company. As of May 21, 2026, ADPT trades at $13.82 with a market cap of $2.03B and a P/E ratio of -41.23. ADPT moved +7.64% today. Year to date, ADPT is -13.67%; over the trailing twelve months it is +49.15%. Its 52-week range spans $4.27 to $20.76. Analyst consensus is strong buy with an average price target of $20.17. Rallies surfaces ADPT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ADPT stock inside the company?

Recent ADPT insider activity includes PISKEL KYLE sold 3.12K, RUBINSTEIN JULIE sold 19.04K, RUBINSTEIN JULIE sold 19.06K, RUBINSTEIN JULIE sold 19.06K, and RUBINSTEIN JULIE sold 19.06K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ADPT Key Metrics

Key financial metrics for ADPT
Metric	Value
Price	$13.82
Market Cap	$2.03B
P/E Ratio	-41.23
EPS	$-0.33
Dividend Yield	0.00%
52-Week High	$20.76
52-Week Low	$4.27
Volume	1
Avg Volume	0
Revenue (TTM)	$295.41M
Net Income	$-49.64M
Gross Margin	75.26%

Recent ADPT Insider Trades

PISKEL KYLE sold 3.12K (~$40.62K) on May 18, 2026.
RUBINSTEIN JULIE sold 19.04K (~$270.90K) on Apr 27, 2026.
RUBINSTEIN JULIE sold 19.06K (~$267.22K) on Apr 24, 2026.
RUBINSTEIN JULIE sold 19.06K (~$261.88K) on Apr 23, 2026.
RUBINSTEIN JULIE sold 19.06K (~$269.32K) on Apr 22, 2026.

Latest ADPT News

Adaptive Biotechnologies Raises MRD Revenue Guidance to $260M–$270M After 53% Q1 Growth — May 5, 2026
Adaptive Biotechnologies Posts Negative P/E –38.02, Price/Sales 8.21 and COO Sells 38K Shares — Apr 17, 2026
Adaptive Biotechnologies’ 2025 Revenue Jumps 55% to $277M as MRD Accelerates — Jan 13, 2026
Adaptive Biotechnologies Q4 Revenue Jumps 51% as MRD Business Hits Positive EBITDA — Feb 6, 2026

ADPT Analyst Consensus

8 analysts cover ADPT: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $20.17.

Common questions about ADPT

Who is trading ADPT stock inside the company?: Recent ADPT insider activity includes PISKEL KYLE sold 3.12K, RUBINSTEIN JULIE sold 19.04K, RUBINSTEIN JULIE sold 19.06K, RUBINSTEIN JULIE sold 19.06K, and RUBINSTEIN JULIE sold 19.06K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ADPT?: Yes. Rallies tracks ADPT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ADPT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ADPT. It does not provide personalized investment advice.